Your browser doesn't support javascript.
loading
Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study.
Wiessing, Lucas; Ferri, Marica; Belácková, Vendula; Carrieri, Patrizia; Friedman, Samuel R; Folch, Cinta; Dolan, Kate; Galvin, Brian; Vickerman, Peter; Lazarus, Jeffrey V; Mravcík, Viktor; Kretzschmar, Mirjam; Sypsa, Vana; Sarasa-Renedo, Ana; Uusküla, Anneli; Paraskevis, Dimitrios; Mendão, Luis; Rossi, Diana; van Gelder, Nadine; Mitcheson, Luke; Paoli, Letizia; Gomez, Cristina Diaz; Milhet, Maitena; Dascalu, Nicoleta; Knight, Jonathan; Hay, Gordon; Kalamara, Eleni; Simon, Roland; Comiskey, Catherine; Rossi, Carla; Griffiths, Paul.
Afiliación
  • Wiessing L; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praça Europa 1, Cais do Sodré, 1249-289, Lisbon, Portugal. Lucas.Wiessing@emcdda.europa.eu.
  • Ferri M; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praça Europa 1, Cais do Sodré, 1249-289, Lisbon, Portugal.
  • Belácková V; Department of Addictology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Carrieri P; National Institute for Mental Health, Prague, Czech Republic.
  • Friedman SR; Uniting Medically Supervised Injecting Centre, Sydney, Australia.
  • Folch C; Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.
  • Dolan K; ORS PACA, Marseille, France.
  • Galvin B; Institute of Infectious Disease Research, National Development and Research Institutes, New York, USA.
  • Vickerman P; Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Agència de Salut Pública de Catalunya (ASPC), Barcelona, Spain.
  • Lazarus JV; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Mravcík V; Program of International Research and Training, National Drug and Alcohol Research Centre, The University of New South Wales (UNSW), Sydney, Australia.
  • Kretzschmar M; Health Research Board, Dublin, Ireland.
  • Sypsa V; School of Social and Community Medicine, University of Bristol, Bristol, UK.
  • Sarasa-Renedo A; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Uusküla A; Barcelona Institute of Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain.
  • Paraskevis D; Department of Addictology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Mendão L; National Institute for Mental Health, Prague, Czech Republic.
  • Rossi D; National Monitoring Centre for Drugs and Addiction, Prague, Czech Republic.
  • van Gelder N; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Mitcheson L; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • Paoli L; Department of Hygiene Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Gomez CD; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Milhet M; Spanish Field Epidemiology Training Program (PEAC), National Centre of Epidemiology, Carlos III Health Institute, Madrid, Spain.
  • Dascalu N; Department of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
  • Knight J; Department of Hygiene Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Hay G; Group of Activists on Treatments (GAT), Lisbon, Portugal.
  • Kalamara E; Intercambios Civil Association and University of Buenos Aires, Buenos Aires, Argentina.
  • Simon R; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praça Europa 1, Cais do Sodré, 1249-289, Lisbon, Portugal.
  • Comiskey C; Leuven Institute of Criminology (LINC), Faculty of Law, University of Leuven, Leuven, Belgium.
  • Rossi C; Centre for Global Governance Studies (GSS), Leuven, Belgium.
  • Griffiths P; French Monitoring Centre for Drugs and Drug Addiction (OFDT), Saint-Denis, France.
Harm Reduct J ; 14(1): 19, 2017 04 22.
Article en En | MEDLINE | ID: mdl-28431584
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 1_medicamentos_vacinas_tecnologias / 2_sustancias_psicoativas Asunto principal: Calidad de la Atención de Salud / Trastornos Relacionados con Sustancias / Reducción del Daño Tipo de estudio: Guideline / Qualitative_research Límite: Humans Idioma: En Revista: Harm Reduct J Año: 2017 Tipo del documento: Article País de afiliación: Portugal
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 1_medicamentos_vacinas_tecnologias / 2_sustancias_psicoativas Asunto principal: Calidad de la Atención de Salud / Trastornos Relacionados con Sustancias / Reducción del Daño Tipo de estudio: Guideline / Qualitative_research Límite: Humans Idioma: En Revista: Harm Reduct J Año: 2017 Tipo del documento: Article País de afiliación: Portugal